Anti-CD14 antibody [EPR3653],Abcam,AB133335
Product Specifications Anti-CD14 antibody [EPR3653] (ab133335) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, WB in human samples. Anti-CD14 antibody [EPR3653] (ab133335) specifically detects CD14 (UniProt ID: P08571; Molecular weight: 37kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-CD14 antibody [EPR3653] (ab133335) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-CD14 antibody [EPR3653] (ab133335) has been cited over 27 times in peer reviewed journals and is trusted by the scientific community. Related Products Antibody clone EPR3653 is also available pre-conjugated to a variety of labels for your convenience - HRP, Alexa Fluor® 594 ( ab195525 , ab314340 ). Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
WB, IHC-P
Platform ID
BAB370688864

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Coreceptor for bacterial lipopolysaccharide (PubMed : 1698311, PubMed : 23264655). In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed : 20133493, PubMed : 22265692, PubMed : 23264655). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed : 8612135). Acts as a coreceptor for TLR2 : TLR6 heterodimer in response to diacylated lipopeptides and for TLR2 : TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway (PubMed : 16880211). Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed : 23880187). See full target information CD14
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.
